See other companies on Welcome to the Jungle

Mendelian

Accelerates diagnoses of rare diseases

Mendelian logo
21-100 employees
  • Healthcare
  • B2B
  • Artificial Intelligence
  • Big data
  • SaaS
Old Street, London, UK

Company mission

We’re helping to end the diagnostic odyssey by bringing timely patient insights to primary care.

Led by a woman
Top investors

22% female employees

Our take

Rare diseases affect over 350 million patients worldwide. Unfortunately, it can take years of research and misdiagnoses before the correct rare disease is identified. This so-called "diagnostic odyssey" is not only causing patients distress and emotional turmoil, but also frustration among clinicians and an enormous financial burden on healthcare systems and associated trusts. This is the problem that Mendelian has set out to overturn.

Mendelian’s specialised screening system, dubbed MendelScreen, incorporates augmented intelligence and data analysis to produce a ranked list of likely causative disease genes based on how closely the patient’s query matches a disease. The company's platform is even more unique as it goes one step further to make "smart suggestions” regarding diagnosis, specialist referral and recommendations for further tests and analysis.

Mendelian's ultimate goal is to provide timely diagnoses for every patient suffering from a rare disease. It continually invests into its service to ensure the reports it provides are optimised for efficiency and data provision.

Steph headshot

Steph

Company Specialist at Welcome to the Jungle

Benefits

  • Pet-friendly office
  • Work from home opportunities
  • Meaningful equity package

Funding (last 2 of 5 rounds)

Mar 2023

$1.8m

GRANT

Feb 2022

$0.5m

GRANT

Total funding: $3.8m

This company has top investors

Leadership

Fran Garcia

(Chairman)

Completed an MBA at INSEAD.

Studied Computer Engineering at Imperial College London.